The world’s leading health organizations supporting celiac disease awareness and education (Celiac Disease Foundation, American Celiac Disease Alliance, Celiac Sprue Association, Gluten Intolerance Group and the National Foundation for Celiac Awareness) applaud the efforts of Alvine Pharmaceuticals and AbbVie in addressing the significant unmet medical need for therapeutic treatment of celiac disease. ALV003 is an investigational oral therapy composed of two recombinant, gluten specific enzymes (a cysteine protease (EP-B2) and a prolyl endopeptidase (PEP)), that degrade gluten in-vitro and in human clinical testing, and may reduce the symptoms and intestinal injury associated with celiac disease in patients attempting to adhere to a gluten-free diet.
5/14/2013
Progress Toward Oral Therapy for Celiac Disease
Recent Posts
- Celiac Safety Act of 2026 Introduced in House of Representatives
- Advocating for Clearer Labeling of Gluten in the U.S.
- Celiac Strong Day 2026: Celebrating the Strength of the Celiac Disease Community
- Advocacy Spotlight: How One Mother Turned Her Family’s Experience into Policy Change in Virginia
Search the archive
Categories
- Advocacy News
- Celiac Disease in the News
- Clinical Trials
- Eat! Gluten-Free
- Featured
- Foundation Press
- iCureCeliac
- Impact Fund
- Marilyn’s Message
- Monthly eNewsletter
- Patient Profile Advocacy Series
- Recipes
- Research
- Research News
- Trending Topics
Marilyn's Message
3/18/2025
Read moreA Bold New Look for the Celiac Disease Foundation
Dear Celiac Disease Foundation Community, For more than three decades, the Celiac Disease Foundation has been dedicated to improving the lives of those affected by celiac disease through research, advocacy, and education. What began as a grassroots effort has grown into a global organization, leading the charge in accelerating diagnosis,...